Charles River Laboratories Intl. (NYSE:CRL) Lowered to “Hold” at ValuEngine

ValuEngine lowered shares of Charles River Laboratories Intl. (NYSE:CRL) from a buy rating to a hold rating in a research note published on Thursday, ValuEngine reports.

CRL has been the topic of several other reports. Leerink Swann initiated coverage on Charles River Laboratories Intl. in a report on Monday, June 10th. They set an outperform rating on the stock. Svb Leerink assumed coverage on Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an outperform rating and a $155.00 price target for the company. Evercore ISI reiterated an outperform rating and issued a $160.00 price target on shares of Charles River Laboratories Intl. in a report on Tuesday, April 30th. Finally, Zacks Investment Research upgraded Charles River Laboratories Intl. from a sell rating to a hold rating in a report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $147.79.

CRL stock traded down $0.79 during midday trading on Thursday, hitting $133.12. 319,978 shares of the company’s stock were exchanged, compared to its average volume of 272,497. The company has a quick ratio of 1.39, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. has a 12-month low of $103.00 and a 12-month high of $149.07. The business has a 50 day moving average of $137.65. The firm has a market capitalization of $6.56 billion, a PE ratio of 22.08, a price-to-earnings-growth ratio of 1.73 and a beta of 1.10.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The company had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. During the same period in the previous year, the business earned $1.62 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts forecast that Charles River Laboratories Intl. will post 6.51 earnings per share for the current fiscal year.

In related news, Director George Massaro sold 1,002 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $131.38, for a total transaction of $131,642.76. Following the completion of the transaction, the director now directly owns 11,204 shares in the company, valued at approximately $1,471,981.52. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider William D. Barbo sold 4,905 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total value of $613,909.80. Following the transaction, the insider now owns 25,859 shares of the company’s stock, valued at $3,236,512.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,047 shares of company stock valued at $1,168,322. 1.80% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. Gabelli Funds LLC lifted its holdings in shares of Charles River Laboratories Intl. by 9.4% during the second quarter. Gabelli Funds LLC now owns 29,000 shares of the medical research company’s stock valued at $4,115,000 after purchasing an additional 2,500 shares during the last quarter. Gamco Investors INC. ET AL lifted its holdings in shares of Charles River Laboratories Intl. by 40.0% during the second quarter. Gamco Investors INC. ET AL now owns 7,000 shares of the medical research company’s stock valued at $993,000 after purchasing an additional 2,000 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Charles River Laboratories Intl. during the second quarter valued at $318,000. Swiss National Bank lifted its holdings in shares of Charles River Laboratories Intl. by 2.4% during the second quarter. Swiss National Bank now owns 89,700 shares of the medical research company’s stock valued at $12,728,000 after purchasing an additional 2,100 shares during the last quarter. Finally, TimesSquare Capital Management LLC lifted its holdings in shares of Charles River Laboratories Intl. by 5.1% during the second quarter. TimesSquare Capital Management LLC now owns 907,850 shares of the medical research company’s stock valued at $128,824,000 after purchasing an additional 44,275 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Bollinger Bands

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.